Evid Invest
Who owns MRKWhat MRK owns

What Merck & Co., Inc. owns

The company's own 13F portfolio · as of 2026-03-31 · long US-listed stakes only — private holdings, bonds and cash are not disclosable on a 13F

$349.4M

disclosed stock portfolio

14

positions

33.6%

in MRNA

Positions, as of 2026-03-31

ordered by filed value · % of book = share of the disclosed stock portfolio · PUT/CALL tags = options positions (share-equivalents), not shares held

#IssuerSharesValue% of book
1MRNAMODERNA INC2.3M$117.3M33.6%
2PERSONALIS INC14.0M$89.5M25.6%
3KYMRKYMERA THERAPEUTICS INC772,165$64.3M18.4%
4ENTRADA THERAPEUTICS INC1.7M$22.0M6.3%
5EIKON THERAPEUTICS INC1.7M$17.6M5%
6AKTIS ONCOLOGY INC952,844$17.0M4.9%
7ALECTOR INC3.5M$7.6M2.2%
8SUTRO BIOPHARMA INC272,351$6.8M1.9%
9EVAXION BIOTECH A/S1.2M$4.5M1.3%
10VRDNVIRIDIAN THERAPEUTICS INC93,414$1.8M0.5%
11XILIO THERAPEUTICS INC105,982$891,3090.3%
12CARISMA THERAPEUTICS INC1.5M$47,8800%
13NEUPHORIA THERAPEUTICS INC10,027$40,8100%
14TUHURA BIOSCIENCES19,445$34,8070%

Source: SEC Form 13F-HR filed by Merck & Co., Inc. (CIK 310158), reporting period 2026-03-31. Values are quarter-end filed marks. Research, not investment advice.

EvidInvest is an independent research and information tool. Figures are calculated from public SEC filings and third-party market data and are provided for informational and educational purposes only. EvidInvest does not provide investment advice, brokerage, or financial services, and is not affiliated with any company it covers. Verify all figures against primary sources before making any decision.